Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2019-12-10 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
108年11月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document contains financial data related to loan balances, endorsements, and guarantees for the company and its subsidiaries for a specific month (November of the 108th year in the Taiwanese calendar, which corresponds to 2019). The data is presented in a tabular format with monetary amounts. The document is very short (615 characters) and appears to be a regulatory disclosure of financial information rather than a full financial report or announcement. It does not contain comprehensive financial statements or management discussion. It is a typical regulatory filing providing specific financial data disclosures.
2019-12-10 Chinese
108年11月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, supervisors, general managers, and their family members. It shows the number of shares held, changes in holdings, and other related data. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full annual or quarterly report, earnings release, or any other report type. The document is a detailed disclosure of insider shareholdings, which corresponds to the category of Director's Dealing (DIRS). The document length is substantial and contains actual data, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is Director's Dealing (DIRS).
2019-12-09 Chinese
108年11月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings and pledges of shares by company insiders, including directors, supervisors, and senior management. It lists the number of shares held at appointment and currently held, as well as pledged shares and related percentages. The document is focused on insider shareholdings and their changes, which corresponds to reporting of personal share transactions by company directors and executives. There is no indication of financial results, meeting materials, or other report types. The document length is 3289 characters, which is relatively short but contains substantive data on insider holdings. Therefore, the document fits best into the category of Director's Dealing (DIRS).
2019-12-09 Chinese
108年第3季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a publicly listed company (杏輝) reporting investment details in overseas subsidiaries for the third quarter of the 108th year (Taiwan calendar, equivalent to 2019). It includes investment amounts, shareholding percentages, and recognized investment gains or losses. The document is short (1078 characters) and appears to be a regulatory disclosure of investment holdings and results rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed management discussion. It is consistent with a regulatory filing or announcement of investment information rather than a full annual or interim report. Given the short length and nature, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories.
2019-11-13 Chinese
108年第3季大陸投資
Regulatory Filings Classification · 85% confidence The document is a detailed tabular disclosure of investment amounts and related financial figures concerning the company's investments in mainland China. It includes specific financial data such as capital amounts, investment methods, cumulative investment amounts, shareholding percentages, investment gains or losses, and regulatory approval limits. The document is relatively short (1499 characters) but contains substantive financial data related to investments rather than just an announcement or summary. It does not appear to be a full annual or interim report, nor a presentation or voting result. The content aligns with a regulatory disclosure of investment details, which typically falls under Regulatory Filings (RNS) as it is a compliance disclosure without the broader scope of a full financial report or audit report. Therefore, the best classification is Regulatory Filings (RNS).
2019-11-13 Chinese
108年第3季財務報告書 — 201904_1734_AI3.pdf
Regulatory Filings
2019-11-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.